1. US Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. FDA
https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574154.htm
(2017).
2. US Food and Drug Administration. FDA briefing document: Oncologic Drugs Advisory Committee meeting; BLA 125646; Tisagenlecleucel, Novartis Pharmaceuticals Corporation. FDA
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf
(2017).
3. Court, E. Novartis' CAR-T gene therapy, the first approved by FDA, to cost $475,000. Market Watch
http://www.marketwatch.com/story/novartis-car-t-gene-therapy-the-first-approved-by-fda-to-be-priced-based-on-cancer-patients-outcomes-2017-08-30
(31 Aug 2017).
4. Herman, B. The cancer drug pricing firestorm. Axios
https://www.axios.com/the-car-t-drug-pricing-firestorm-2479635241.html
(31 Aug 2017).
5. Mitchell, D. Patients For Affordable Drugs launches campaign demanding fair pricing of new Novartis cancer drug. Patients For Affordable Drugs
http://www.patientsforaffordabledrugs.org/2017/08/17/patients-for-affordable-drugs-launches-campaign-demanding-fair-pricing-of-new-cancer-drug/
(17 Aug 2017).